ALEXANDRIA, Va., Sept. 8 -- United States Patent no. 12,729,189, issued on Sept. 8, was assigned to NXERA PHARMA UK Ltd. (Cambridgeshire, Great Britain).
"GPR52 modulator compounds" was invented by Sarah Joanne Bucknell (Cambridge, Great Britain), Stephen Paul Watson (Cambridge, Great Britain) and Michael Alistair O'Brien (Cambridge, Great Britain).
According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosures herein relate to novel compounds of Formula (1): or a salt thereof, wherein Q, V, L, W, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with GPR52 receptors."
The patent was filed on Aug. 31, 2021, under Applica...